Abstracts tagged "Disease Activity"

Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0432 • ACR Convergence 2024
Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
Marion couderc¹, celine lambert², sabrina hamroun³, denis gallot⁴, Nathalie Costedoat-chalumeau⁵, Laure Gossec⁶, Gaëlle Guettrot-Imbert⁷, Veronique LE GUERN⁷, Christophe Richez⁸, MArtin Soubrier⁹ and Anna Molto¹⁰, ¹CHU de Clermont-Ferrand, Clermont-Ferrand, ²chu clermont ferrand, clermont ferrand, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, ⁵University Paris Cité, Paris, France, ⁶Sorbonne Université, Paris, France, ⁷Cochin Hospital, Paris, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁰Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
Abstract Number: 0578 • ACR Convergence 2024
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Muhammad Saeed¹, HIna Ahmed² and Aziza Ahmed³, and Arthritis Carte Foundation Faculty, ¹Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, ²Central Park Medical College, Lahore, Pakistan, ³Rashid Latif Medical College, Lahore, Pakistan
Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1351 • ACR Convergence 2024
Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
Woo-Joong KIM¹, Chanseok PARK², Seungmo KOO², Jae-Young CHEONG² and Jiho KIM², ¹Chung-Ang University Hospital, Seoul, Korea, Seoul, Republic of Korea, ²Hongik University, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires regular monitoring to prevent joint damage and systemic complications. However, the shortage of trained…
Abstract Number: 1446 • ACR Convergence 2024
Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?
Emrah Koç¹, Burak Okyar², Sibel Bakırcı³, suade Özlem Badak², Ali Nail Demir⁴, İsmail Uçar⁴, Gökhan Sargın⁵, Servet Yüce⁶ and Emine Duygu Ersözlü¹, ¹Adana City Training and Research Hospital, Adana, Turkey, ²Adana City Training and Research Hospital, Adana, ³Antalya training and research hospital, Antalya, Turkey, ⁴Mersin City Hospital, Mersin, Turkey, ⁵Aydin Adnan Menderes University, Aydın, Turkey, ⁶Şırnak Provincial Health Directorate Public Health Department, Şırnak, Turkey
Background/Purpose: The study aimed to evaluate changes in enthesis areas in ankylosing spondylitis patients in remission for at least six months, using either NSAIDs or…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 2169 • ACR Convergence 2024
Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study
Paul Studenic¹, Nadine Schwab², Günther Zauner², Thi Lan Vi Tran³ and Helga Lechner-Radner⁴, ¹Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, ²dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…
Abstract Number: 2363 • ACR Convergence 2024
“How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Atul Deodhar¹, Elena Nikiphorou², Abhijeet Danve³, Stephen Hall⁴, Vanessa Taieb⁵, Diana Voiniciuc⁶, Marina Magrey⁷ and Xenofon Baraliakos⁸, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²King's College London, London, United Kingdom, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Cabrini Medical Centre, Monash University, and Emeritus Research, Melbourne, Victoria, Australia, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Slough, United Kingdom, ⁷Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Two phase 3 studies were conducted where treatment…
Abstract Number: 2621 • ACR Convergence 2024
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
David Cheng¹, Vidul Panickan², Andrew Cagan³, Gregory McDermott⁴, Mary Jeffway³, Ying Qi⁵, Feng Liu³, Michael Weinblatt⁶, Nancy Shadick⁵, Tianxi Cai⁷ and Katherine Liao³, ¹Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Brookline, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
Abstract Number: 0453 • ACR Convergence 2024
Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
Andrea Pluma¹, Linda Rüegg², Sabrina Hamroun³, Axel Finckh⁴, Yvette Meissner⁵ and Frauke Foerger⁶, ¹Vall d'Hebron University Hospital, Barcelona, Spain, ²Inselspital, Bern University Hospital, Bern, Switzerland, ³Cochin University Hospital, Paris, Ile-de-France, France, ⁴Geneva University Hospital, Geneva, Switzerland, ⁵Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁶University hospital Bern /Inselspital Bern, Bern, Switzerland
Background/Purpose: Counselling patients with rheumatic and musculoskeletal diseases (RMD) in the phase of reproduction, pregnancy and breastfeeding is a challenging task. The potential risk of…
Abstract Number: 0579 • ACR Convergence 2024
Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
Judith Rademacher¹, Murat Torgutalp², Lynn zur Bonsen¹, Dominika Pohlmann¹, Hildrun Haibel¹, Fabian Proft¹, Mikhail Protopopov³, Uwe Pleyer¹, Valeria Rios Rodriguez¹ and Denis Poddubnyy⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charite Universitatsmedizin - Berlin, Berlin, Germany, ³Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Acute anterior uveitis (AAU) and axial spondyloarthritis (axSpA) are closely linked, with AAU being the most common extra-musculoskeletal manifestation of axSpA. Up to half…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 1238 • ACR Convergence 2024
Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², seoidin McKittrick³, Robert Harrington⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland, ⁴St. James's Hospital, Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: One of the most significant unmet needs in the management of those with Polymyalgia Rheumatica (PMR) is the lack of a disease stratification tool…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].